X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2186) 2186
Publication (134) 134
Book Review (13) 13
Book Chapter (5) 5
Newsletter (5) 5
Magazine Article (4) 4
Data Set (3) 3
Newspaper Article (3) 3
Dissertation (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1745) 1745
male (1035) 1035
female (1019) 1019
idarubicin (952) 952
middle aged (905) 905
idarubicin - administration & dosage (891) 891
adult (846) 846
hematology (820) 820
antineoplastic combined chemotherapy protocols - therapeutic use (806) 806
oncology (776) 776
aged (644) 644
cytarabine - administration & dosage (640) 640
index medicus (475) 475
leukemia, myeloid, acute - drug therapy (471) 471
remission induction (460) 460
chemotherapy (450) 450
adolescent (409) 409
treatment outcome (385) 385
idarubicin - therapeutic use (362) 362
acute myelogenous leukemia (330) 330
idarubicin - adverse effects (288) 288
daunorubicin (287) 287
antineoplastic combined chemotherapy protocols - adverse effects (281) 281
cancer (278) 278
acute myeloid-leukemia (273) 273
anthracyclines (263) 263
therapy (253) 253
antineoplastic combined chemotherapy protocols - administration & dosage (237) 237
acute myeloid leukemia (234) 234
cytarabine (234) 234
leukemia (230) 230
etoposide - administration & dosage (229) 229
acute disease (227) 227
disease-free survival (222) 222
daunorubicin - administration & dosage (208) 208
prognosis (197) 197
idarubicin - pharmacology (193) 193
animals (190) 190
daunorubicin - analogs & derivatives (190) 190
leukemia, promyelocytic, acute - drug therapy (186) 186
pharmacology & pharmacy (183) 183
recurrence (183) 183
child (182) 182
leukemia, myeloid - drug therapy (175) 175
doxorubicin (170) 170
aged, 80 and over (168) 168
cytosine-arabinoside (166) 166
survival analysis (166) 166
survival rate (159) 159
antineoplastic agents - therapeutic use (158) 158
antibiotics, antineoplastic - therapeutic use (156) 156
dose-response relationship, drug (153) 153
leukemia, myeloid, acute - mortality (149) 149
cytarabine - therapeutic use (147) 147
cytarabine - adverse effects (142) 142
daunorubicin - therapeutic use (142) 142
young adult (135) 135
aml (134) 134
child, preschool (134) 134
tretinoin - administration & dosage (134) 134
combined modality therapy (131) 131
trial comparing idarubicin (131) 131
administration, oral (130) 130
vidarabine - analogs & derivatives (130) 130
adult patients (121) 121
drug administration schedule (121) 121
retrospective studies (121) 121
acute promyelocytic leukemia (119) 119
antibiotics, antineoplastic - administration & dosage (119) 119
transplantation (118) 118
mitoxantrone - administration & dosage (116) 116
medicine & public health (110) 110
time factors (108) 108
leukemia, myeloid, acute - pathology (107) 107
drug evaluation (105) 105
idarubicin - pharmacokinetics (105) 105
mice (104) 104
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (101) 101
antibiotics, antineoplastic - adverse effects (100) 100
survival (100) 100
vidarabine - administration & dosage (99) 99
infant (98) 98
follow-up studies (97) 97
apoptosis (96) 96
hematopoietic stem cell transplantation (95) 95
leukemia, myeloid, acute - genetics (95) 95
risk factors (95) 95
acute nonlymphocytic leukemia (94) 94
trans-retinoic acid (94) 94
antibiotics, antineoplastic - pharmacology (91) 91
colony-stimulating factor (91) 91
remission (91) 91
trial (90) 90
bone-marrow transplantation (89) 89
daunorubicin - adverse effects (89) 89
relapse (87) 87
p-glycoprotein (86) 86
pharmacokinetics (86) 86
cyclophosphamide - administration & dosage (85) 85
tumor cells, cultured (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2082) 2082
Japanese (36) 36
Chinese (26) 26
German (14) 14
Spanish (13) 13
French (8) 8
Russian (7) 7
Italian (6) 6
Polish (5) 5
Hungarian (4) 4
Czech (2) 2
Portuguese (2) 2
Turkish (2) 2
Dutch (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 12/2015, Volume 220, Issue Pt A, pp. 425 - 437
Drug delivery through thermosensitive liposomes (TSL) in combination with hyperthermia (HT) has shown great potential. HT can be applied locally forcing TSL to... 
Triggered drug release | Idarubicin | Thermosensitive liposome | Mild hyperthermia | ADULT PATIENTS | DRUG-DELIVERY | ACUTE MYELOGENOUS LEUKEMIA | DOXORUBICIN DELIVERY | ACUTE MYELOID-LEUKEMIA | TEMPERATURE-SENSITIVE LIPOSOMES | CELL-LINES | CHEMISTRY, MULTIDISCIPLINARY | BREAST-CANCER | IN-VITRO | PHARMACOLOGY & PHARMACY | TRIAL COMPARING IDARUBICIN | Temperature | Skin Neoplasms - drug therapy | Humans | Melanoma, Experimental - drug therapy | Melanoma, Experimental - metabolism | Dose-Response Relationship, Drug | Lipids - chemistry | Antibiotics, Antineoplastic - chemistry | Doxorubicin - analogs & derivatives | Hyperthermia, Induced | Drug Compounding | Idarubicin - administration & dosage | Idarubicin - chemistry | Doxorubicin - administration & dosage | Idarubicin - metabolism | Skin Neoplasms - pathology | Drug Stability | Mice, Inbred C57BL | Solubility | Melanoma, Experimental - pathology | Polyethylene Glycols - administration & dosage | Skin Neoplasms - metabolism | Antibiotics, Antineoplastic - administration & dosage | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Kinetics | Liposomes | Antibiotics, Antineoplastic - metabolism | Hydrogen-Ion Concentration | Drugs | Anthracyclines | Drug delivery systems | Hyperthermia | Fever | Vehicles | Tumors
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 10/2010, Volume 116, Issue 17, pp. 3171 - 3179
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 1023 - 1034
Survivin is expressed in tumor cells, including acute myeloid leukemia (AML), regulates mitosis, and prevents tumor cell death. The antisense oligonucleotide... 
Cytarabine | Medicine & Public Health | Oncology | Antisense | Idarubicin | Pharmacology/Toxicology | Acute myeloid leukemia | CELLS | APOPTOSIS | SURVIVIN EXPRESSION | CANCER | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | CARCINOMA | PROGRESSION | Recurrence | Demography | Oligonucleotides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - blood | Cytarabine - therapeutic use | Idarubicin - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Idarubicin - pharmacokinetics | Male | Oligonucleotides - adverse effects | Antineoplastic Agents - therapeutic use | Cytarabine - adverse effects | Oligonucleotides - pharmacokinetics | Oligonucleotides, Antisense - blood | Cytarabine - pharmacokinetics | Idarubicin - adverse effects | Antineoplastic Agents - adverse effects | Oligonucleotides, Antisense - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Antineoplastic Agents - pharmacokinetics | Inhibitor of Apoptosis Proteins - metabolism | Cytarabine - blood | Idarubicin - therapeutic use | Oligonucleotides, Antisense - pharmacokinetics | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Oligonucleotides, Antisense - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents - blood | Oligonucleotides - blood | Complications and side effects | Dosage and administration | Studies | Research | Drug therapy | Cancer therapies | Pharmaceutical sciences | Tumors | Index Medicus | idarubicin | cytarabine | acute myeloid leukemia | antisense
Journal Article
Blood, ISSN 0006-4971, 07/2013, Volume 122, Issue 1, pp. 37 - 43
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 01/2012, Volume 9, Issue 1, pp. 14 - 28
As 95% of all prescriptions are for orally administered drugs, the issue of oral absorption is central to the development of pharmaceuticals. Oral absorption... 
ranitidine | mucoadhesion | hydrophobic drugs | griseofulvin | cyclosporin A | idarubicin | chitosan amphiphiles | hydrophilic drugs | transcellular transport | oral absorption | AQUEOUS-SOLUTIONS | PERMEABILITY | VESICLES | MONOLAYERS | P-GLYCOPROTEIN | DELIVERY | IN-VITRO | TRANSPORT | CYCLOSPORINE-A | EPITHELIAL CACO-2 CELLS | PHARMACOLOGY & PHARMACY | Intestinal Mucosa - metabolism | Nanoparticles - chemistry | Rats, Wistar | Ranitidine - pharmacokinetics | Humans | Drug Carriers - administration & dosage | Idarubicin - pharmacokinetics | Male | Drug Carriers - analysis | Anti-Ulcer Agents - blood | Quaternary Ammonium Compounds - chemistry | Griseofulvin - blood | Intestinal Absorption | Anti-Ulcer Agents - pharmacokinetics | Cyclosporine - blood | Intestinal Mucosa - cytology | Griseofulvin - pharmacokinetics | Griseofulvin - metabolism | Antifungal Agents - pharmacokinetics | Antifungal Agents - metabolism | Cyclosporine - pharmacokinetics | Idarubicin - administration & dosage | Antibiotics, Antineoplastic - pharmacokinetics | Chitosan - analogs & derivatives | Cyclosporine - metabolism | Griseofulvin - administration & dosage | Caco-2 Cells | Idarubicin - metabolism | Drug Carriers - metabolism | Adhesiveness | Nanoparticles - ultrastructure | Rats | Anti-Ulcer Agents - administration & dosage | Ranitidine - metabolism | Antibiotics, Antineoplastic - administration & dosage | Animals | Chitosan - chemistry | Ranitidine - blood | Intestine, Small - cytology | Anti-Ulcer Agents - metabolism | Cyclosporine - administration & dosage | Hydrophobic and Hydrophilic Interactions | Drug Carriers - pharmacokinetics | Intestine, Small - metabolism | Ranitidine - administration & dosage | Antibiotics, Antineoplastic - metabolism | Antifungal Agents - administration & dosage | Antifungal Agents - blood
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2013, Volume 88, Issue 11, pp. 961 - 966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin,... 
PHASE-III TRIAL | SOUTHWEST-ONCOLOGY-GROUP | DOSE CYTOSINE-ARABINOSIDE | GROUP-B | ARA-C | DAUNORUBICIN | HEMATOLOGY | CANCER | CHEMOTHERAPY | MODULATION | INDUCTION TREATMENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Nausea - chemically induced | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Arabinonucleosides - administration & dosage | Idarubicin - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Adenine Nucleotides - administration & dosage | Idarubicin - therapeutic use | Drug Eruptions - etiology | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Cytarabine - administration & dosage | Adenine Nucleotides - adverse effects | Induction Chemotherapy - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Pilot Projects | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Consolidation Chemotherapy - adverse effects | Anthracyclines | Index Medicus | AML | idarubicin | cytarabine | frontline therapy | clofarabine
Journal Article